Glypvilo (Vildagliptin)

Glypvilo is an oral medication that contains the active ingredient vildagliptin. It is marketed in the European Union as a prescription drug, classified as a DPP‑4 inhibitor for the management of type 2 diabetes mellitus. The product’s strength and dosage form are not disclosed, but it is intended for oral administration under medical supervision. Patients receive Glypvilo according to individualized treatment plans that consider glycemic targets and concomitant therapies.

Glypvilo is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive glycemic control strategy.

- Used in adults with type 2 diabetes when diet and exercise alone are insufficient. - Can be combined with other oral antidiabetic agents such as metformin, sulfonylureas, or thiazolidinediones. - May be considered when a patient requires a DPP‑4 inhibitor to improve post‑prandial glucose control. - Intended for use in conjunction with lifestyle modifications, including diet and physical activity.

Like all medications, Glypvilo may cause side effects, which are generally categorized by frequency and severity.

Common: - Upper respiratory tract infection. - Headache. - Nasopharyngitis. - Mild gastrointestinal discomfort such as nausea or abdominal pain.

Serious: - Pancreatitis (severe abdominal pain). - Severe allergic reactions, including angioedema or anaphylaxis. - Hepatic dysfunction. - Hypersensitivity rash or skin eruptions.

Healthcare providers should assess several precautionary factors before prescribing Glypvilo to ensure safe use.

- Evaluate renal function, as dose adjustment may be required in impaired kidneys. - Review hepatic status, especially in patients with a history of liver disease. - Monitor for signs of pancreatitis, including persistent abdominal pain. - Use cautiously in patients with a history of severe allergic reactions. - Consider pregnancy and breastfeeding status; safety data are limited. - Assess overall cardiovascular risk, although no specific contraindication is established.

Glypvilo can interact with other medicines, influencing its effectiveness or increasing the risk of adverse events.

Avoid: - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise vildagliptin levels. - Concomitant use with other DPP‑4 inhibitors, as combined effect is not recommended. - Medications known to cause pancreatitis (e.g., GLP‑1 receptor agonists).

Use with caution: - Diuretics, especially thiazides, which may affect blood glucose control. - Anticoagulants, as glycemic fluctuations can alter INR. - Beta‑blockers, which may mask hypoglycemia symptoms. - NSAIDs, which can affect renal function when combined with vildagliptin in patients with renal impairment.